Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05250895 · ClinicalTrials.gov registry record · Early Phase 1

BOLD MRI and FMISO PET for the Assessment of Hypoxic Tumor Microenvironment in Patients with Oligometastatic Liver Cancer Undergoing Yttirum-90 Selective Internal Radiation Therapy

A Early Phase 1 study of Hepatocellular Carcinoma and BCLC Stage B Hepatocellular Carcinoma, sponsored by Emory University.

Completed
Registry status
Early Phase 1
Development phase
9
Enrollment target
1
Study location

NCT05250895: Completed Early Phase 1 study of Hepatocellular Carcinoma and BCLC Stage B Hepatocellular Carcinoma, sponsored by Emory University.

NCT05250895 is a Early Phase 1 study of Hepatocellular Carcinoma and BCLC Stage B Hepatocellular Carcinoma that has completed, run by Emory University. The registered enrollment target is 9 participants, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05250895, a Early Phase 1 study of Hepatocellular Carcinoma and BCLC Stage B Hepatocellular Carcinoma, has completed, sponsored by Emory University.

COMPLETED
Registry status
Early Phase 1
Development phase
9 participants
Enrollment target
1
Study location

Study Summary

This early phase I trial evaluates the use of hypoxia (lack of oxygen) as a measure in determining the outcome of Y90 selective internal radiation therapy in patients with liver cancer that has spread to a limited number of sites (oligometastatic). Radioembolization with Y90 is a minimally invasive procedure that combines embolization and radiation therapy to treat metastatic liver cancer. Tiny beads filled with radioactive isotope Y-90 are placed inside the blood vessel that provide blood supply to the tumor. This will block the blood flow to the tumor cells while providing a high radiation dose without harming healthy normal tissue.

Primary Outcome

Threshold \<1.0 R2 tumor to normal ratio (no unit) as a cutoff for hypoxia

Conditions Studied

Hepatocellular Carcinoma BCLC Stage B Hepatocellular Carcinoma BCLC Stage C Hepatocellular Carcinoma BCLC Stage A Hepatocellular Carcinoma

Interventions

  • PROCEDURE Biopsy
  • PROCEDURE Positron Emission Tomography
  • PROCEDURE Dynamic Contrast-Enhanced Magnetic Resonance Imaging
  • OTHER 18F-Fluoromisonidazole

Study Locations (1)

Georgia

  • Emory University Hospital/Winship Cancer Institute - Atlanta

Trial Details

FieldValue
Enrollment Target 9 participants
Start Date 2022-04-28
Est. Completion 2025-02-26
Phase Early Phase 1
Emory University

1,208 total trials

What the finished NCT05250895 record still lists

NCT05250895 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (96% lower).

The record links to 4 conditions, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Biopsy is the first listed.

NCT05250895 reports a single indexed study location in Georgia.

Frequently Asked Questions

What is clinical trial NCT05250895 about?

NCT05250895 is a clinical study titled "BOLD MRI and FMISO PET for the Assessment of Hypoxic Tumor Microenvironment in Patients with Oligometastatic Liver Cancer Undergoing Yttirum-90 Selective Internal Radiation Therapy". This early phase I trial evaluates the use of hypoxia (lack of oxygen) as a measure in determining the outcome of Y90 selective internal radiation therapy in patients with liver cancer that has spread to a limited number of sites (oligometastatic). Radioembolization with Y90 is a minimally invasive ...

What is the current status of trial NCT05250895?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 9 participants. The study started on 2022-04-28. Estimated completion is 2025-02-26.

What conditions does trial NCT05250895 study?

This clinical trial studies the following conditions: Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, BCLC Stage A Hepatocellular Carcinoma.

What interventions are being tested in trial NCT05250895?

The interventions under investigation include: Biopsy (PROCEDURE), Positron Emission Tomography (PROCEDURE), Dynamic Contrast-Enhanced Magnetic Resonance Imaging (PROCEDURE), 18F-Fluoromisonidazole (OTHER).

Who is sponsoring clinical trial NCT05250895?

This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05250895 being conducted?

This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hepatocellular Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05250895's enrollment target sits among peer trials

9 142nd of 145 higher than 4 of 145 other Hepatocellular Carcinoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Hepatocellular Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT05250895, the US trial registry maintained by the National Library of Medicine. NCT05250895 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.